Gilead Sciences Eyes $2 Billion Deal for Autoimmune Biotech Ouro Medicines
Gilead Sciences eyes up to $2B deal for autoimmune biotech Ouro Medicines, with $1.5B upfront + milestones, amid strong stock & deal spree.
/ 15 items
#GILD↓
Gilead Sciences to Acquire Arcellx in $7.8 Billion Deal to Boost Cancer Treatment Options
Gilead Sciences announces acquisition of Arcellx for $7.8B, gaining full control of promising CAR T-cell therapy anito-cel for multiple myeloma patients, with deal expected to close in Q2 2026.
Gilead Acquires Repare's Cancer Drug for $30 Million
Gilead Sciences purchases RP-3467, a promising cancer treatment targeting BRCA mutations, from Repare Therapeutics in a deal worth up to $30 million.
Trump Administration Secures Drug Price Cuts from Nine Major Pharmaceutical Companies
Nine pharmaceutical giants including Merck and GSK agree to slash U.S. drug prices to match other wealthy nations under new Trump administration deals, offering discounts up to 70%.
Arcus and Gilead Halt Cancer Trial After Treatment Fails to Extend Patient Survival
Arcus Biosciences discontinues Phase 3 STAR-221 cancer trial after independent review finds experimental treatment unlikely to improve survival for gastric and esophageal cancer patients.
Anito-cel Shows High Efficacy and Impressive Two-Year Survival Rates in Relapsed/Refractory Multiple Myeloma
New data confirms Arcellx’s anito-cel is a powerful and safe CAR-T cell therapy for relapsed or refractory multiple myeloma, showing deep, durable responses.